A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
I-Mab Biopharma US Limited
Kansas State University
Inova Health Care Services
Cedars-Sinai Medical Center
Medical University of South Carolina
Celldex Therapeutics
National Cancer Institute (NCI)
Massachusetts General Hospital
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Jiangsu HengRui Medicine Co., Ltd.
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Massachusetts General Hospital
Fred Hutchinson Cancer Center
Mirror Biologics, Inc.
Virginia Commonwealth University
IGF Oncology, LLC
University of Illinois at Chicago
Stanford University
Azienda USL 4 Prato
The Christie NHS Foundation Trust
University of Texas Southwestern Medical Center
University of Toronto
Massachusetts General Hospital
Jules Bordet Institute
Memorial Sloan Kettering Cancer Center
Northwestern University
Hadassah Medical Organization
National Institutes of Health Clinical Center (CC)
Poniard Pharmaceuticals
Pharmacyclics LLC.
FeRx